Literature DB >> 8251314

Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.

G H Bock1, J R Ongkingco, L T Patterson, J Ruley, L R Schroepfer, D L Nelson.   

Abstract

Although a cellular immune pathogenesis is suspected in idiopathic nephrotic syndrome of childhood (INS), there is scant direct evidence of in vivo immune activation. In order to investigate cytokine cascade activation in INS, soluble interleukin-2 receptor (sIL-2R) in plasma and urine was characterized and its levels measured in INS patients during relapse. Immunochemically detectable sIL-2R had a molecular mass of 35-46 kDa in both serum and urine and the molecule appears to be excreted intact; the pI was 5.05. INS patients had elevated serum sIL-2R levels compared with adult normal controls (845 +/- 97 vs. 373 +/- 47 U/ml, P = 0.001) and were significantly higher than previously published age-matched controls. Urinary excretion of sIL-2R was 47.2 +/- 13 U/mg creatinine in patients. Both the sIL-2R excretion rate and the fractional excretion of sIL-2R were positively correlated with the excretion of albumin (P = 0.02 and 0.002, respectively). These increased serum and urine levels occurred whether relapse was or was not associated with an intercurrent illness. We conclude that: (1) despite increased sIL-2R excretion during INS relapse, serum levels are significantly elevated; (2) while the elevated urinary levels could result from enhanced intrarenal production, they more likely reflect the increased serum levels; (3) the elevated sIL-2R levels support an immune pathogenesis in INS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251314     DOI: 10.1007/bf00852533

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  37 in total

1.  Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis.

Authors:  N Keicho; K Kitamura; F Takaku; H Yotsumoto
Journal:  Chest       Date:  1990-11       Impact factor: 9.410

2.  The molecular basis for the generation of the human soluble interleukin 2 receptor.

Authors:  L A Rubin; F Galli; W C Greene; D L Nelson; G Jay
Journal:  Cytokine       Date:  1990-09       Impact factor: 3.861

3.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

Authors:  D Degiannis; J R Seibold; M Czarnecki; J Raskova; K Raska
Journal:  Arthritis Rheum       Date:  1990-03

4.  Decreased production of interleukin-1 by monocytes from patients with lipoid nephrosis.

Authors:  K Matsumoto
Journal:  Clin Nephrol       Date:  1989-06       Impact factor: 0.975

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

Review 7.  The soluble interleukin-2 receptor: biology, function, and clinical application.

Authors:  L A Rubin; D L Nelson
Journal:  Ann Intern Med       Date:  1990-10-15       Impact factor: 25.391

8.  Depression of endostreptosin, streptolysin O and streptozyme antibodies in patients with idiopathic nephrosis with and without a nephrotic syndrome.

Authors:  K Lange; U Ahmed; G Seligson; A Grover
Journal:  Clin Nephrol       Date:  1981-06       Impact factor: 0.975

9.  Soluble IL-2 receptor in patients with primary nephrotic syndrome.

Authors:  I Ohno; H Gomi; H Matsuda; H Nakano; H Matsumoto; K Kodama; T Shibasaki; F Ishimoto; O Sakai
Journal:  Nihon Jinzo Gakkai Shi       Date:  1991-05

10.  Enhanced suppressor T cell activity resulting in increased IgM and decreased IgG productions in children with minimal change nephrotic syndrome.

Authors:  C H Chen; K H Hsieh; P P Lee
Journal:  Int J Pediatr Nephrol       Date:  1987 Apr-Jun
View more
  1 in total

1.  The concurrent presentation of minimal change nephrotic syndrome and aplastic anemia.

Authors:  Elissa Michele Abrams; Ian W Gibson; Tom David Blydt-Hansen
Journal:  Pediatr Nephrol       Date:  2008-09-25       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.